初见端倪的肝纤维化靶向治疗

陈平圣; 刘静

doi:10.3969/j.issn.1001-5256.2013.11.004

初见端倪的肝纤维化靶向治疗

DOI: 10.3969/j.issn.1001-5256.2013.11.004

陈平圣,
刘静

东南大学医学院病理学与病理生理学系

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2858
- HTML全文浏览量: 10
- PDF下载量: 611
- 被引次数: 0
出版历程
- 收稿日期: 2013-07-30
- 出版日期: 2013-11-20

Targeted therapy of liver fibrosis on the horizon

Department of Pathology and Physiopathology, Medical School of Southeast University

摘要

摘要: 近年肝纤维化靶向治疗研究进展迅速,但如何将药物特异地投送至靶细胞并发挥理想效应仍然有诸多挑战。就肝纤维化靶向治疗研究中所涉及的靶细胞和靶分子及其选择原则、载体选择和修饰的一般原则及其方法、疗效和毒副作用检测等问题进行了阐述,并指出肝纤维化乃多细胞参与、多因子释放、多种信号通路激活的复杂病理过程,所以选择合适的靶点是靶向治疗的关键,而正确构建靶向投递系统是治疗成功的保证。
- 肝硬化 /
- 药物载体 /
- 靶向治疗
Abstract: Over the past few years, significant advances have occurred in the targeted therapy of liver fibrosis. However, it is still a big challenge to deliver drugs to target cells and exert desirable therapeutic effect. The research on targeted therapy of liver fibrosis, including the types of target cells and target molecules and their selection rules, the general rules and methods for carrier selection and modification, and the evaluation of treatment outcomes and toxic or side effects, is reviewed. It is pointed out that liver fibrosis is a complex pathological process involving multiple cells, cytokines, and signaling pathways, so selecting suitable therapeutic target is the key to targeted therapy, and proper development of targeted delivery system is the guarantee for successful treatment.
- liver cirrhosis /
- drug carriers /
- targeted therapy

HTML全文

参考文献(1)

[1]ELLIS EL, MANN DA.Clinical evidence for the regression of liver fibrosis[J].J Hepatol, 2012, 56 (5) :1171-1180.[2]SHEN YY, TANG QJ.Clinical efficacy of compound Chinese medicine preparation in treating liver fibrosis among patients with hepatitis B[J].J Changchun Univ Tradit Chin Med, 2011, 27 (3) :421-422. (in Chinese) 沈英宇, 唐秋君.中药复方制剂治疗乙肝后肝纤维化临床观察[J].长春中医药大学学报, 2011, 27 (3) :421-422.[3]XIE JR, LIU Y, LIANG GY, et al.Effects of Rouganjian decoctin on liver function and serum liver fibrosis in patients with liver fibrosis induced by chronic hepatitis B[J].Jilin Tradit Chin Med, 2012, 32 (7) :688-689. (in Chinese) 谢晶日, 刘洋, 梁国英, 等.柔肝煎对慢性乙型肝炎肝纤维化患者肝功能及血清肝纤维化指标的影响[J].吉林中医药, 2012, 32 (7) :688-689.[4]POELSTRA K, SCHUPPAN D.Targeted therapy of liver fibrosis/cirrhosis and its complications[J].J Hepatol, 2011, 55 (3) :726-728.[5]LI J, FAN R, ZHAO S, et al.Reactive oxygen species released from hypoxic hepatocytes regulates MMP-2 expression in hepatic stellate cells[J].Int J Mol Sci, 2011, 12 (4) :2434-2447.[6]KMIEC'Z.Cooperation of liver cells in health and disease[J].Adv Anat Embryol Cell Biol, 2001, 161:III-XIII, 1-151.[7]ROWE IA, GALSINH SK, WILSON GK, et al.Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication[J].Hepatology, 2013, Jun 14.[Epub ahead of print][8]HONDA E, PARK A, YOSHIDA K, et al.Myofibroblasts:biochemical and proteomic approaches to fibrosis[J].Tohoku J Exp Med, 2013, 230 (2) :67-73.[9]TAGUCHI K, FUJIKAWA N, KOMATSU M, et al.Keap1 degradation by autophagy for the maintenance of redox homeostasis[J].Proc Natl Acad Sci U S A, 2012, 109 (34) :13561-13566.[10]SZABO G, BALA S.MicroRNAs in liver disease[J].Nat Rev Gastroenterol Hepatol, 2013.[Epub ahead of print][11]HE Y, HUANG C, LIN X, et al.MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases[J].Biochimie, 2013, 95 (7) :1355-1359.[12]JOPLING C.Liver-specific microRNA-122:Biogenesis and function[J].RNA Biol, 2012, 9 (2) :137-142.[13]VETTORI S, Gay S, Distler O.Role of MicroRNAs in Fibrosis[J].Open Rheumatol J, 2012, 6 (Suppl 1:M9) :130-139.[14]LI Q, YAN Z, LI F, et al.The improving effects on hepatic fibrosis of interferon-γliposomes targeted to hepatic stellate cells[J].Nanotechnology, 2012, 23 (26) :265101.[15]REETZ J, GENZ B, MEIER C, et al.Development of adenoviral delivery systems to target hepatic stellate cells in vivo[J].PLoS One, 2013, 8 (6) :e67091.[16]CHEN PS, LIU F, DING FG, et al.Inhibition of liver fibrosis in vitro using vitamin A-coupled liposomes to deliver MMP-2 siRNA[OL].Sciencepaper Online, http://www.paper.edu.cn/index.php/default/releasepaper/content/201212-502. (in Chinese) 陈平圣, 刘凤, 丁粉干, 等.VitA偶联脂质体包裹MMP-2 siRNA靶向预防肝纤维化的体外研究[OL].[2012-12-20].中国科技论文在线, http://www.paper.edu.cn/releasepaper/content/201212-502.[17]YAMADA Y, HASHIDA M, HAYASHI Y, et al.An approach to transgene expression in liver endothelial cells using a liposomebased gene vector coated with hyaluronic acid[J].J Pharm Sci, 2013, 102 (9) :3119-3127.[18]WANG W, YUAN Z.Recent development of liver targeted drug delivery system based on nanotechnology[J].Polymer Bulletin, 2013, 25 (1) :137-154. (in Chinese) 王蔚, 袁直.肝靶向纳米给药系统的最新研究进展[J].高分子通报, 2013, 25 (1) :137-154.

施引文献

资源附件(0)

访问统计